Dietary antioxidants during cancer chemotherapy: Impact on chemotherapeutic effectiveness and development of side effects

Nutrition and Cancer

Volumn 37, Issue 1, 2000, Pages 1-18

  Conklin, K A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BLEOMYCIN; CISPLATIN; DAIDZEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; FREE RADICAL; GENISTEIN; GLUTAMINE; GLUTATHIONE TRANSFERASE; PROTEIN TYROSINE KINASE; QUERCETIN; REACTIVE OXYGEN METABOLITE; SELENIUM; UBIQUINONE;

ALOPECIA; ANTIOXIDANT ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL PROLIFERATION; CLINICAL TRIAL; CYTOTOXICITY; DIET SUPPLEMENTATION; ENZYME INHIBITION; HUMAN; LUNG FIBROSIS; META ANALYSIS; MUTAGENESIS; NEPHROTOXICITY; OXIDATIVE STRESS; REVIEW;

EID: 0033847986     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/S15327914NC3701_1     Document Type: Review

References (215)

1. Growth-related lipid peroxidation in turnout microsomal membranes and mitochondria
2. Regulation of cell division in a human glioma cell clone by arachidonic acid and α-tocopherolquinone
3. Influence of n-3 fatty acids on the growth of human breast cancer cells in vitro: Relationship to peroxides and vitamin E
4. Fatty acid metabolism and cell proliferation. V. Evaluation of pathways for the generation of lipid peroxides
5. Effect of polyunsaturated fatty acids and antioxidants on lipid peroxidation in tissue cultures
6. Polyunsaturated, fatty acids, vitamin E, and the proliferation of aortic smooth muscle cells
7. Triglycerides, lipid droplets, and lysosomes in aorta smooth muscle cells during the control of cell proliferation with polyunsaturated fatty acids and vitamin E
8. Dipyridamol: An antioxidant that promotes the proliferation of aorta smooth muscle cells
9. Fatty acid specificity in the inhibition of cell proliferation and its relationship to lipid peroxidation and prostaglandin biosynthesis
10. Fatty acids and their prostaglandin derivatives: Inhibitors of proliferation in aortic smooth muscle cells
11. Effect of dietary fat on growth of MCF-7 and MDA-MB231 human breast carcinomas in athymic nude mice: Relationship between carcinoma growth and lipid peroxidation product levels
12. Dietary fish oil inhibits human breast carcinoma growth: A function of increased lipid peroxidation
13. Dietary menhaden oil enhances mitomycin C antitumor activity toward human mammary carcinoma MX-1
14. The antioxidant and prooxidant activity in ascites tumors
15. Functional and structural alterations of liver ergastoplasmic membranes during DL-ethionine hepatocarcinogenesis
16. Studies on lipid peroxidation in normal and tumour tissues. The Novikoff rat liver tumour
17. Studies on lipid peroxidation in normal and turnout tissues. The Yoshida rat liver tumour
18. 2+-induced lipid peroxidation and swelling in the mitochondria isolated from ascites tumor cells
19. Lipid peroxidation of the microsomal fraction and extracted microsomal lipids from DAB-induced hepatomas
20. Antioxidant status and lipid peroxidation in athymic mice xenografted with two types of human tumors
21. Lipid peroxidation products and vitamin and trace element status in patients with cancer before and after chemotherapy including adriamycin. A preliminary study
22. Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression of cancer
23. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients
24. Plasma vitamin E and β-carotene concentrations during radiochemotherapy preceding bone marrow transplantation
25. 5-Hydroxymethyluracil excretion, plasma TBARS and plasma antioxidant vitamins in adriamycin-treated patients
26. Effect of etoposide (VP16-213) on lipid peroxidation and antioxidant status in a high-dose radiochemotherapy regimen
27. Deteriorating free radical-trapping capacity and antioxidant status in plasma during bone marrow transplantation
28. Lipoperoxides as an index of free radical activity in bone marrow transplant recipients. Preliminary observations
29. Effects of anthracyclin-based chemotherapy on total plasma antioxidant capacity in small cell lung cancer patients
30. Increase in free radical generation and lipid peroxidation following chemotherapy in patients with cancer
31. Lipid peroxides in the polychemotherapy of cancer patients
32. Oxidant and antioxidant levels in the erythrocytes of breast cancer patients treated with CMF
33. Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity
34. Supplementation with antioxidants prior to bone marrow transplantation
35. The DNA cleavage mechanism of iron-bleomycin. Kinetic resolution of strand scission from base propenal release
36. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure
37. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours
38. Oxidative mechanisms in carcinogenesis
39. α-Tocopherol pretreatment increases adriamycin bone marrow toxicity
40. The enhancement of 5-fluorouracil antimetabolic activity by Leucovorin, menadione, and α-tocopherol
41. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21(WAF1/CIP1) via C/EBPβ
42. Vitamin E increases the growth inhibitory and differentiating effects of tumor therapeutic agents on neuroblastoma and glioma cells in culture
43. Vitamin E enhances the chemotherapeutic effects of adriamycin on human prostatic carcinoma cells in vitro
44. Modification of the effect oftamoxifen, cis-platin, DTIC, and interferon-α2b on human melanoma cells in culture by a mixture of vitamins
45. Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination
46. Combined effects of vitamin E (α-tocopherol) and cisplatin on the growth of murine neuroblastoma in vitro
47. Adriamycin: The role of lipid peroxidation in cardiac toxicity and tumor response
48. Effect of α-tocopherol on the cardiotoxicity of adriamycin in the rat
49. Induction of apoptosis in human breast cancer cells by tocopherols and tocotrienols
50. Effect of palm oil tocotrienols on epidermal growth factor receptor protein tyrosine kinase activity in human breast cancer cells
51. Effects of vitamins on lipid peroxidation and suppression of DNA synthesis induced by adriamycin in Ehrlich cells
52. Indication of reduced doxorubicin-induced cardiac toxicity by additional treatment with antioxidative substances
53. 10)
54. Effect of vitamin E against adriamycin-induced toxicity in rabbits
55. Amelioration of adriamycin-induced cardiotoxicity in rabbits by prenylamine and vitamins A and E
56. The effect of vitamin E and selenium on doxorubicin (adriamycin)-induced delayed toxicity in mice
57. The effects of α-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice
58. 10 or α-tocopherol reduces the acute toxicity of anthramycin in mice
59. Adriamycin: Amelioration of toxicity by α-tocopherol
60. Effect of high dose α-tocopherol and α-tocopherol acetate pretreatment in adriamycin (doxorubicin)-induced toxicity and tissue distribution
61. Failure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit
62. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants
63. Evaluation of vitamin E and selenium protection against chronic adriamycin toxicity in rabbits
64. Protective effects of vitamin E against bleomycin-induced genotoxicity in head and neck cancer patients in vitro
65. In vitro protective effects of chemopreventive agents against bleomycin-induced genotoxicity in lymphoblastoid cell lines and peripheral blood lymphocytes of head and neck cancer patients
66. The effect of antioxidants on bleomycin treatment in in vitro and in vivo genotoxicity assays
67. Modification of cisplatin toxicity by antioxidants
68. Acute cardiac toxicity in patients after doxorubicin treatment and the effect of combined tocopherol and nifedipine pretreatment
69. Erhohung des frei-ionisierten zytoplasmatischen Calciums als Ursache der Adriamycin-Kardiomyopathie
70. Clinical and pharmacologic investigation of the effects of α-tocopherol on adriamycin cardiotoxicity
71. Prospective study of tocopherol prophylaxis for anthracycline cardiac toxicity
72. High-dose α-tocopherol as a preventive of doxorubicin-induced alopecia
73. Vitamin E in the treatment of chemotherapy-induced mucositis
74. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro
75. Sodium ascorbate potentiates the growth inhibitory effect of certain agents on neuroblastoma cells in culture
76. Ascorbic acid increases drag accumulation and reverses vincristine resistance of human non-small-cell lung cancer cells
77. 3 vitamin pre-treatment
78. Potentiation of BCNU by vitamin C in a murine model of CNS leukemia
79. Ascorbic acid and adriamycin toxicity
80. Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs
81. Effects of N-acetyl-L-cysteine and ascorbic acid on mutagen-induced chromosomal sensitivity in patients with head and neck cancers
82. Inhibition of mitomycin C-induced sister chromatid exchanges by vitamin C in vivo
83. Vitamin C intake influences the bleomycin-induced chromosome damage assay: Implications for detection of cancer susceptibility and chromosome breakage syndromes
84. Protective effect of endogenous coenzyme Q on both lipid peroxidation and respiratory chain inactivation induced by an adriamycin-iron complex
85. Protective effect of exogenous coenzyme Q against damage by adriamycin in perfused rat liver
86. Approaches that mitigate doxorubicin-induced delayed adverse effects on mitochondrial function in rat hearts: Liposome-encapsulated doxorubicin or combination therapy with antioxidants
87. 10 enzymes in mitochondria of the myocardium
88. 10 enzymes, succinoxidase and NADH-oxidase, by adriamycin and other quinones having antitumor activity
89. 10 protection
90. 10 enzymes
91. 10 and implication for the cardiotoxicity of adriamycin in cancer patients
92. An anthracycline antibiotic-induced cardiomyopathy in rabbits
93. Adriamycin: Energy metabolism and mitochondrial oxidation in the heart of treated rabbits
94. 10
95. 10 from electrocardiographic abnormalities caused by the toxicity of adriamycin in the rat
96. 10 of the acute toxicity of adriamycin in mice
97. 10 and adriamycin toxicity in mice
98. 10 on the adriamycin-induced cardiotoxicity in the isolated perfused rat heart
99. 10 on the survival time and lipid peroxidation of adriamycin (doxorubicin)-treated mice
100. 10
101. 10 on anthracyclines cardiotoxicity: Control study in children with acute lymphoblastic leukemia and non-Hodgkins lymphoma
102. 10
103. 10 in clinical medicine and in immunomodulation
104. In vivo modulation of several anticancer agents by β-carotene
105. β-Carotene reduces toxicity and carcinogenicity of cyclophosphamide in control and tumor-bearing mice
106. The protective effect of β-carotene on genotoxicity induced by cyclophosphamide
107. Effect of β-carotene on clastogenic effects of mitomycin C methyl methanesulphonate, and bleomycin in Chinese hamster ovary cells
108. Carotenoids reduce the chromosomal damage induced by bleomycin in human cultured lymphocytes
109. Glutathione monoesters
110. Some procedures to reduce cis-platinum toxicity reduce antitumor activity
111. Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia
112. Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin
113. Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug
114. A preliminary clinical experience with reduced glutathione as protector against cisplatin toxicity
115. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats
116. Thiol and thioether suppression of cis-platinum-induced nephrotoxicity in rats bearing the Walker 256 carcinosarcoma
117. Protective effect of reduced glutathione against cis-dichlorodiammine platinum(II)-induced nephrotoxicity and lethal toxicity
118. Protection against cisplatin toxicity by administration of glutathione ester
119. Prevention of doxorubicin myocardial toxicity in mice by reduced glutathione
120. Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide
121. Prevention of cyclophosphamide-induced urotoxicity by reduced glutathione and its effect on acute toxicity and antitumor activity of the alkylating agent
122. Peripheral neurotoxicity following high-dose cisplatin with glutathione: Clinical and neurophysiological assessment
123. A feasibility study of cisplatin administration with low-volume hydration and glutathione protection in the treatment of ovarian carcinoma
124. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer
125. A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity
126. A feasibility study of high-dose cisplatin and 5-fluorouracil with glutathione protection in the treatment of advanced colorectal cancer
127. Phase I trial of cisplatin in combination with glutathione
128. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial
129. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomized trial
130. Beneficial effect of acetylcysteine on cisplatin nephrotoxicity in rats
131. N-acetylcysteine modifies cis-dichlorodiammineplatinum-induced effects in bladder cancer cells
132. Antioxidants specifically inhibit cisplatin cytotoxicity of human malignant glioma cells
133. Protection with N-acetyl-L-cysteine (NSC- 1I1I80) against isophosphamide (NSC-I09724) toxicity and enhancement of therapeutic effect in early murine L12I0 leukemia
134. The effect of N-acetyl cysteine on cyclophosphamide cystitis
135. The effect of N-acetylcysteine on cyclophosphamide immunoregulation and antitumor activity
136. Effect of N-acetylcysteine on the antitumor activity of cyclophosphamide against Walker-256 carcinosarcoma in rats
137. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine
138. Effect of sulfhydryl-containing compounds on the antitumor effects of adriamycin
139. The efficacy of N-acetylcysteine in preventing doxorubicin-induced cardiomyopathy in dogs
140. Usefulness of a free radical scavenger in preventing doxorubicin-induced heart failure in dogs
141. Comparison of the effectiveness of 1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles
142. Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria
143. Prophylaxis of ifosfamide toxicity with oral acetylcysteine
144. N-acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer
145. The control of ifosfamide-induced hematuria with N-acetylcysteine in patients with advanced carcinoma of the lung
146. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine
147. Attempt to prevent doxorubicin-induced acute human myocardial morphologic damage with acetylcysteine
148. Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism
149. Glutamine facilitates chemotherapy while reducing toxicity
150. Effect of supplemental dietary glutamine on methotrexate concentrations in tumors
151. Effect of a glutamine-supplemented enteral diet on methotrexate-induced enterocolitis
152. Disparate effects of 5-fluorouracil on the ileum and colon of enterally fed rats with protection by dietary glutamine
153. Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer
154. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy
155. Oral glutamine to prevent chemotherapy-induced stomatitis: A pilot study
156. Oral glutamine in the prevention of chemotherapy-induced gastrointestinal toxicity
157. Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen
158. Effect of coadministration of selenite on the toxicity and antitumor activity of cis-diamminedichloroplatinum(II) given repeatedly to mice
159. The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumor activity
160. Effect of selenium in combination with cis-diamminedichloroplatinum(II) in the treatment of murine fibrosarcoma
161. Selenium-induced protection against cis-diam minedichloroplatinum(II) nephrotoxicity in mice and rats
162. Selenium supplementation decreases the pro-oxidant and cardiotoxicity effects of adriamycin in the rat
163. Abrogation of adriamycin-induced cardiotoxicity by selenium in rabbits
164. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients
165. Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein
166. Antioxidant and antipromotional effects of the soybean isoflavone genistein
167. Neutrophil palming by granulocyte colony-stimulating factor and its modulation by protein kinase inhibitors
168. Induction of mammalian topoisomerase II-dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol
169. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II
170. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II
171. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: Evidence for distinct drug interaction domains on topoisomerase II
172. Effect of genistein on topoisomerase activity and on the growth of [VAL 12]Ha-ras-transformed NIH 3T3 cells
173. The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells
174. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells
175. 2-M
176. Inhibition of murine bladder tumorigenesis by soy isoflavones via alteration in the cell cycle, apoptosis, and angiogenesis
177. Inhibition of growth and induction of differentiation of metastatic melanoma cells in vitro by genistein: Chemosensitivity is regulated by cellular p53
178. Genistein inhibits tumour cell growth in vitro but enhances mitochondrial reduction of tetrazolium salts: A further pitfall in the use of the MTT assay for evaluating cell growth and survival
179. Tyrosine kinase inhibitor-induced differentiation of K-562 cells: Alteration of cell cycle and cell surface phenotype
180. Induction and differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein
181. Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract
182. Inhibitors of tyrosine phosphorylation induce apoptosis in human leukemic cell lines
183. Induction of mouse thymocyte apoptosis by inhibitors of tyrosine kinases is associated with dephosphorylation of nuclear proteins
184. Protein tyrosine phosphorylation is mandatory for DC-40-mediated rescue of germinal center B cells from apoptosis
185. Genistein, a specific inhibitor of tyrosine-specific protein kinases
186. Soy isoflavonoids and cancer prevention. Underlying biochemical and pharmacological issues
187. Genistein-mediated attenuation of tamoxifen-induced antagonism from estrogen receptor-regulated genes
188. Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells
189. Phyto-oestrogens and Western diseases
190. Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: An altered response in accumulation-defective resistant cells
191. Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells
192. Soy-derived antiapoptotic fractions protect gastrointestinal epithelium from damage caused by methotrexate treatment in the rat
193. Polyphenols: Chemistry, dietary sources, metabolism, and nutritional significance
194. Reduction potential of flavonoid and model phenoxyl radicals. Which ring in flavonoids is responsible for antioxidant activity?
195. Tyrosine protein kinase activity in the DMBA-induced rat mammary tumor: Inhibition by quercetin
196. The effect of quercetin on the phosphorylation activity of the Rous sarcoma vires-transforming gene product in vitro and in vivo
197. The effects of the bioflavonoid quercetin on squamous cell carcinoma of head and neck origin
198. Bioflavonoid interaction with rat uterine type 11 binding sites and cell growth inhibition
199. The effect of flavonoids on aerobic glycolysis and growth of tumor cells
200. 1 phase of the cell cycle
201. Quercetin mediates the down-regulation of mutant p53 in the human breast cancer cell line MDA-MB468
202. Inhibitory effect of quercetin on the synthesis of a possibly cell-cycle-related 17-kDa protein, in human colon cancer cells
203. The effect of quercetin on cell cycle progression and growth of human gastric cancer cells
204. Type II oestrogen binding sites in acute lymphoid and myeloid leukaemias: Growth inhibitory effect of oestrogen and flavonoids
205. Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen-binding sites in primary ovarian tumours and cultured cells
206. Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites
207. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target
208. Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum(II)
209. Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C
210. Enhanced anti-proliferative action of busulphan by quercetin on human leukaemia cell line K562
211. The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth
212. Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by quercetin
213. Current role of protective agents in cancer treatment
214. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer
215. The dioxopiperazine derivatives, their leukemogenic potential and other biological effects